Misregulation of gene cohorts, which is caused by aberrant chromatin features and is observed in various cancers, has spurred the development and use of epigenetic anti-cancer drugs. Here, we argue that, in addition to small-molecule inhibitors that target chromatin regulators, synthetic reader-effectors that are recruited to abnormal chromatin features have the potential to correct gene misregulation in epigenetic therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lungu, C., Pinter, S., Broche, J., Rathert, P. & Jeltsch, A. Nat. Commun. 8, 649 (2017).
Tekel, S. J., Barrett, C., Vargas, D. & Haynes, K. A. Biochemistry 57, 4707–4716 (2018).
Delachat, A. M.-F. et al. Cell Chem. Biol. 25, 51–56.e6 (2018).
Sanchez, O. F., Mendonca, A., Carneiro, A. D. & Yuan, C. ACS Sens. 2, 426–435 (2017).
Bracken, A. P. & Helin, K. Nat. Rev. Cancer 9, 773–784 (2009).
Jene-Sanz, A. et al. Mol. Cell. Biol. 33, 3951–3961 (2013).
Dawson, M. A. & Kouzarides, T. Cell 150, 12–27 (2012).
Tekel, S. J. & Haynes, K. A. Nucleic Acids Res. 45, 7555–7570 (2017).
Li, H. et al. Oncotarget 5, 587–598 (2014).
Ahuja, N., Sharma, A. R. & Baylin, S. B. Annu. Rev. Med. 67, 73–89 (2016).
Mahara, S. et al. Proc. Natl Acad. Sci. USA 113, E3735–E3744 (2016).
McGarvey, K. M. et al. Cancer Res. 66, 3541–3549 (2006).
Kagey, J. D., Kapoor-Vazirani, P., McCabe, M. T., Powell, D. R. & Vertino, P. M. Mol. Cancer Res. 8, 1048–1059 (2010).
Gibaja, V. et al. Oncogene 35, 558–566 (2016).
Baker, T. et al. Oncotarget 6, 32646–32655 (2015).
Stuckey, J. I. et al. Nat. Chem. Biol. 12, 180–187 (2016).
Gough, S. M. et al. Cancer Discov. 4, 564–577 (2014).
Falahi, F., Sgro, A. & Blancafort, P. Front. Oncol. 5, 22 (2015).
Maeder, M. L. et al. Nat. Biotechnol. 31, 1137–1142 (2013).
Kungulovski, G. et al. Epigenetics Chromatin 8, 12 (2015).
Wang, G. G. et al. Nature 459, 847–851 (2009).
Olney, K. C., Nyer, D. B., Vargas, D. A., Wilson Sayres, M. A. & Haynes, K. A. BMC Syst. Biol. 12, 83 (2018).
Jullien, D. et al. J. Cell Sci. 129, 2673–2683 (2016).
Sato, Y., Stasevich, T. J. & Kimura, H. Methods Mol. Biol. 1861, 91–102 (2018).
Lara, H. et al. J. Biol. Chem. 287, 29873–29886 (2012).
Acknowledgements
The authors are supported by start-up support from the Wallace H. Coulter Department of Biological Engineering at the Emory School of Medicine.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Baskin, N.L., Haynes, K.A. Chromatin engineering offers an opportunity to advance epigenetic cancer therapy. Nat Struct Mol Biol 26, 842–845 (2019). https://doi.org/10.1038/s41594-019-0299-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41594-019-0299-6
